Lutetium oxodotreotide (177Lu-Dotatate) for the treatment of unresectable or metastatic progressive gastroenteropancreatic neuroendocrine tumors: a cost-effectiveness analysis for Scotland
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Lutetium oxodotreotide (177Lu-Dotatate) for the treatment of unresectable or metastatic progressive gastroenteropancreatic neuroendocrine tumors: a cost-effectiveness analysis for Scotland
Authors
Keywords
-
Journal
BMC CANCER
Volume 21, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-01-05
DOI
10.1186/s12885-020-07710-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies
- (2019) NaNa Keum et al. Nature Reviews Gastroenterology & Hepatology
- Impact of neuroendocrine morphology on cancer outcomes and stage at diagnosis: a UK nationwide cohort study 2013–2015
- (2019) Tracey S. E. Genus et al. BRITISH JOURNAL OF CANCER
- Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis
- (2018) Ruben Mujica-Mota et al. HEALTH TECHNOLOGY ASSESSMENT
- 1335TiPCOMPETE trial: Peptide receptor radionuclide therapy (PRRT) with 177Lu-edotreotide vs. everolimus in progressive GEP-NET
- (2018) M E Pavel et al. ANNALS OF ONCOLOGY
- Gastroenteropancreatic Neuroendocrine Tumors
- (2018) Mauro Cives et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
- (2017) Jonathan Strosberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas
- (2017) Bryan Oronsky et al. NEOPLASIA
- Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States
- (2017) Arvind Dasari et al. JAMA Oncology
- Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study
- (2016) James C. Yao et al. JOURNAL OF CLINICAL ONCOLOGY
- Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
- (2016) James C Yao et al. LANCET
- ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site
- (2016) M. Pavel et al. NEUROENDOCRINOLOGY
- A Tale of Two Thresholds: A Framework for Prioritization within the Cancer Drugs Fund
- (2016) Simon Leigh et al. VALUE IN HEALTH
- Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis
- (2014) S Ward et al. HEALTH TECHNOLOGY ASSESSMENT
- Elicitation of health state utilities in neuroendocrine tumours
- (2012) P. Swinburn et al. JOURNAL OF MEDICAL ECONOMICS
- Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
- (2011) Eric Raymond et al. NEW ENGLAND JOURNAL OF MEDICINE
- Role of Somatostatins in Gastroenteropancreatic Neuroendocrine Tumor Development and Therapy
- (2010) Kjell E. Öberg et al. GASTROENTEROLOGY
- Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib
- (2009) G Mickisch et al. BRITISH JOURNAL OF CANCER
- Health state utilities for non small cell lung cancer
- (2008) Beenish Nafees et al. Health and Quality of Life Outcomes
- Health state utility scores in advanced non-small cell lung cancer
- (2008) Scott Doyle et al. LUNG CANCER
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now